Thursday October 5, 7:01 am Eastern Time
Press Release
SOURCE: Lexicon Genetics Incorporated
Lexicon Genetics and Tularik Enter Into Functional
Genomics Collaboration
THE WOODLANDS, Texas, Oct. 5 /PRNewswire/ -- Lexicon Genetics Incorporated (Nasdaq: LEXG - news) announced
today a multi-year functional genomics research agreement with Tularik Inc. (Nasdaq: TLRK - news) under Lexicon's
OmniBank® Internet Universal (TM) program. Under the agreement, Tularik will have access to conditional knockouts and
gene specific knockouts, generated using Lexicon's proprietary gene targeting program, with genetic alterations directed at
specific drug targets selected by Tularik. Tularik will also have access to Lexicon's OmniBank library of 90,000 knockout
mouse clones for use in determining the function of genes that represent potential drug targets. Financial terms were not
disclosed.
``We are pleased to welcome Tularik, a recognized leader in small molecule drug discovery, to our growing list of
collaborators,'' stated Arthur Sands, M.D., Ph.D., President and Chief Executive Officer at Lexicon Genetics. ``Tularik's gene
regulation approach to drug discovery is ideally suited to benefit from Lexicon's proprietary technology.''
``Lexicon's expertise in rapidly generating gene alterations in mammalian models will be important to Tularik in its quest to
discover superior drug targets,'' said Andrew Perlman, M.D., Ph.D., Executive Vice President of Tularik. ``Lexicon's knockout
technology will help us accelerate our drug discovery process across therapeutic areas.''
Lexicon Genetics Incorporated is a leader in defining the functions of genes for drug discovery using large-scale knockout
mouse technology. Complementary to its gene-specific custom knockout technology, Lexicon has invented high-throughput
genome-wide gene trapping technology to discover thousands of genes and expand its OmniBank (R) library of tens of
thousands of knockout mouse clones. The Company uses an integrated platform of functional genomic technologies to
accelerate large-scale analysis of mammalian gene function for drug discovery. Lexicon's Internet exchange, www.lexgen.com,
enables researchers worldwide to access the OmniBank library and form collaborations with Lexicon to discover
pharmaceutical products based on genes and knowledge of their functions. Lexicon has established drug discovery
collaborations with Abgenix, Inc. and Arena Pharmaceuticals, Inc., a LexVision (TM) collaboration with Bristol-Myers Squibb
Company, and functional genomics and OmniBank alliances with many pharmaceutical and biotechnology companies, including
American Home Products, The R.W. Johnson Pharmaceutical Research Institute of Johnson & Johnson, Pharmacia Corp.,
Boehringer Ingelheim Pharmaceuticals, N.V. Organon, DuPont Pharmaceuticals and Millennium Pharmaceuticals, Inc., as well
as leading academic institutions worldwide. Additional Company information is available at www.lexicon-genetics.com.
Statements in this press release that are not strictly historical are ``forward-looking'' statements as defined in the Private
Securities Litigation Reform Act of 1995. The actual results may differ materially from those projected in the forward-looking
statements due to the risks and uncertainties that exist in Lexicon's filings with the Securities and Exchange Commission. The
Company disclaims any obligations to update the statements in this press release.
Lexicon Genetics Contacts:
Jennifer Wolford
Manager, Corporate Communications
Lexicon Genetics Incorporated
281/364-0100
jwolford@lexgen.com
Doug MacDougall
Libby Wright
Feinstein Kean Healthcare
617/577-8118
dmacdougall@fkhealth.com
SOURCE: Lexicon Genetics Incorporated |
